Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stewart A Factor

Showing results (141-150 of 198) with videos related to

Pageof 20
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|August 1, 2020
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's diseaseR Mark Richardson, Krystof S Bankiewicz, Chadwick W Christine, et al.
Human Genetics|January 23, 2008
Exploring gene-environment interactions in Parkinson's diseaseColin C McCulloch, Denise M Kay, Stewart A Factor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 15, 2017
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiomeErin M Hill-Burns, Justine W Debelius, James T Morton, et al.
Genetic Testing|October 6, 2006
Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's diseaseDenise M Kay, Tom D Bird, Cyrus P Zabetian, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 3, 2018
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medicationsAlberto J Espay, Michael T Guskey, James C Norton, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 23, 2021
Discussion of Research Priorities for Gait Disorders in Parkinson's DiseaseNicolaas I Bohnen, Rui M Costa, William T Dauer, et al.
The Lancet. Psychiatry|July 3, 2017
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trialKaren E Anderson, David Stamler, Mat D Davis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 16, 2022
Reply to: "Letter on Discussion of Gait Research"Nicolaas I Bohnen, Rui M Costa, William T Dauer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 13, 2019
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesiaHubert H Fernandez, David Stamler, Mat D Davis, et al.
Journal of Neurosurgery|October 12, 2019
Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRIVibhash D Sharma, Yarema B Bezchlibnyk, Faical Isbaine, et al.
Pageof 20

Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
Journal of Neurology, Neurosurgery, and Psychiatry|August 1, 2020
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's diseaseR Mark Richardson, Krystof S Bankiewicz, Chadwick W Christine, et al.
Human Genetics|January 23, 2008
Exploring gene-environment interactions in Parkinson's diseaseColin C McCulloch, Denise M Kay, Stewart A Factor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 15, 2017
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiomeErin M Hill-Burns, Justine W Debelius, James T Morton, et al.
Genetic Testing|October 6, 2006
Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's diseaseDenise M Kay, Tom D Bird, Cyrus P Zabetian, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 3, 2018
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medicationsAlberto J Espay, Michael T Guskey, James C Norton, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 23, 2021
Discussion of Research Priorities for Gait Disorders in Parkinson's DiseaseNicolaas I Bohnen, Rui M Costa, William T Dauer, et al.
The Lancet. Psychiatry|July 3, 2017
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trialKaren E Anderson, David Stamler, Mat D Davis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 16, 2022
Reply to: "Letter on Discussion of Gait Research"Nicolaas I Bohnen, Rui M Costa, William T Dauer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 13, 2019
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesiaHubert H Fernandez, David Stamler, Mat D Davis, et al.
Journal of Neurosurgery|October 12, 2019
Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRIVibhash D Sharma, Yarema B Bezchlibnyk, Faical Isbaine, et al.
Pageof 20